# LEO Pharma A/S > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/leopharma). ## Overview LEO Pharma A/S is a Denmark-based pharmaceutical company focused on dermatology and skin-health medicines. Its business includes researching, developing, manufacturing, and commercializing prescription treatments used by patients and healthcare professionals in multiple regions. ## Products & services • Prescription dermatology medicines • Topical and systemic skin-disease treatments • In-licensed and partnered dermatology assets • Clinical development of dermatology programs • Manufacturing and supply of pharmaceutical products - **Dermatology medicines** (80%) — Prescription therapies for chronic and acute skin diseases, including branded medicines sold through healthcare channels. - **In-licensed products** (15%) — Externally originated dermatology assets commercialized through licensing and partnership agreements. - **Development pipeline** (5%) — Clinical-stage dermatology programs and related research activity that can become future products. - Prescription dermatology medicines - Topical and systemic skin-disease treatments - In-licensed and partnered dermatology assets - Clinical development of dermatology programs - Manufacturing and supply of pharmaceutical products ## Customers LEO Pharma sells primarily to healthcare providers and the pharmaceutical distribution channel rather than to end consumers directly. Its products are used by dermatologists, hospitals, clinics, and pharmacies that prescribe or dispense treatments for skin diseases. The company also depends on licensing and collaboration partners for selected programs and geographic reach. - **Dermatology specialists** (primary) — Dermatologists and specialist prescribers buy LEO Pharma medicines for skin diseases such as psoriasis and related conditions. - **Hospitals and clinics** (primary) — Hospital outpatient and specialty clinics use branded prescription treatments for patients needing physician-managed therapy. - **Pharmacies and wholesalers** (secondary) — Distribution partners stock and supply the company's medicines to patients and healthcare providers. - **License partners** (secondary) — Partners buy rights, co-commercialization options, or development access for selected dermatology assets. - Dermatologists treating chronic inflammatory skin disease - Hospitals and clinics using specialist prescription medicines - Pharmacies and distributors that dispense branded drugs - Healthcare systems that procure reimbursed dermatology therapies - License and collaboration partners for selected programs ## Geography LEO Pharma operates as an international pharmaceutical business headquartered in Denmark, with commercial and development activity spanning North America, Europe, and other regions. The report excerpt points to material exposure to the U.S. market and additional regions for approved dermatology products, which makes regulatory access and reimbursement important drivers of geographic performance. - Headquartered in Denmark with global operating functions - Commercial footprint spans North America and Europe - U.S. market is important for approved dermatology products - Additional regions support international product commercialization - Manufacturing and supply activities are tied to Denmark sites ## Strategy LEO Pharma's strategy centers on expanding its dermatology portfolio through development, licensing, and commercial partnerships. The report highlights in-licensed assets and collaborations that broaden the product base while preserving optionality in markets outside core territories. - **Build the dermatology pipeline** (medium-term) — A broader pipeline reduces reliance on a small number of branded products and supports longer-term growth. - **Use licensing and partnerships** (short-term) — External programs can extend the portfolio without requiring all rights to be developed in-house. - **Strengthen international commercialization** (medium-term) — Broader geographic reach increases the addressable market for specialized dermatology products. - Expand the dermatology portfolio through external in-licensing - Advance clinical development of oral and specialty programs - Use partnerships to broaden ex-U.S. commercialization reach - Focus capital on differentiated skin-disease therapies - Strengthen product strategy and international operations ## Risks LEO Pharma faces typical pharmaceutical risks from clinical development uncertainty, regulatory approval, and market access for specialty medicines. Its dependence on dermatology assets and external partnerships also creates concentration and execution risk if development timelines slip or partnered programs do not progress as planned. - **Clinical development failure** [high] — New dermatology programs can fail to meet efficacy or safety expectations, delaying or preventing commercialization. - **Regulatory and reimbursement pressure** [high] — Specialty medicines depend on approvals, label breadth, and payer coverage to reach patients. - **Partner concentration** [medium] — The company relies on licensing and collaboration structures for some assets and rights. - **Manufacturing and supply disruption** [medium] — Pharmaceutical products require consistent quality control and uninterrupted production. - Clinical trial outcomes may fail to support approval or labeling - Regulatory and reimbursement decisions can limit market access - Dependence on partnered assets creates execution and rights risk - Manufacturing quality and supply continuity are critical - Competition in dermatology can pressure product adoption ## Accounting Key accounting judgments for LEO Pharma include capitalizing or expensing development-related costs, measuring in-licensed intangible assets, and accounting for partnership-linked transaction values. The report also highlights restatements and updated definitions for working capital and net debt, showing that presentation and classification choices can affect comparability across periods. - **In-licensed intangible assets** — Can materially affect operating profit and balance-sheet asset values - **Development costs** — Affects reported R&D expense and future amortization - **Inventory valuation** — Impacts cost of sales and gross profit - **Derivatives and hedging** — Affects finance income/expense and OCI volatility - Development and licensing judgments affect intangible asset values - Partnership proceeds and gains can flow through operating income - Inventory write-downs matter for obsolete pharmaceutical stock - Restatements affect comparability of working capital and debt - Hedge and foreign exchange accounting affect reported volatility --- *Last updated: 2026-10-24T15:11:59.727528+00:00*